Loading...

Purified anti-human CCL13 (MCP-4) Antibody

Pricing & Availability
Clone
3G4 (See other available formats)
Regulatory Status
RUO
Other Names
Monocyte chemeotactic protein 4 (MCP4), CKβ10, New CC chemokine 1 (NCC1), Small inducible cytokine subfamily a, member 13 (SCYA13)
Isotype
Mouse IgG1, κ
Ave. Rating
Submit a Review
Product Citations
publications
3G4_Purified_CCL13_Antibody_122818.PNG
  • 3G4_Purified_CCL13_Antibody_122818.PNG
Cat # Size Price Save
537602 500 µg ¥127,820
Description

Human CCL13 (MCP-4) was initially identified in a library constructed from human fetal mRNA. CCL13 shares a high similarity with CCL2 (MCP-1, 61%), CCL7 (MCP-3, 58%), and CCL8 (MCP-2, 55%). CCL13 is constitutively expressed at high levels in the small intestine, colon, and lung. Original data showed that CCL13 was less effective than MCP-1 and MCP-3 in monocyte and lymphocyte chemoattraction, but equivalent to eotaxin as a chemoattractant for eosinophils. Chemokines are very important in the inflammatory process, initially in the influx of PMN by CXC chemokines and subsequently chemoattracting monocytes where the MCPs participate, including CCL13. The bioactivity of pro-inflammatory chemokines is regulated by MMPs in order to regulate the influx of different cell subpopulations. In the case of CCL13, it is inactivated by MMP-12 by truncation at position 4-5 generating a CCR antagonist and decreasing the arrival of monocytes. CCL13 binds to CCR2, and this receptor also binds to CCL2, CCL8, CCL7, CCL11, CCL24, and CCL26. CCL13 is involved in inflammatory diseases such as rheumatoid arthritis (RA), atherosclerosis, and asthma. High levels of CCL13 have been detected in the synovial fluid of patients with RA, in serum of asthmatic patients, and in plasma of patients with symptomatic carotid atherosclerosis.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Human
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Recombinant protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

ELISA Capture - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by ELISA assay. For ELISA Capture applications, a concentration range of 0.4 - 3 µg/mL is recommended. To obtain a linear standard curve, serial dilutions of CCL13 (MCP4) recombinant protein ranging from 3.9 to 250 pg/mL is recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The pure 3G4 (Cat. No. 537602) antibody is useful as the capture antibody in a sandwich ELISA assay, paired with biotinylated 8C12 (Cat. No. 537704) and Lyophilized CCL13 (MCP4) (Cat. No. 587509). 

RRID
AB_2783351 (BioLegend Cat. No. 537602)

Antigen Details

Structure
Chemokine
Distribution

Epithelial cells, endothelial cells, fibroblasts, chondrocytes, macrophages

Function
CCL13 chemoattract monocytes, eosinophils, CD4, and CD8 T cells. CCL13 induces histamine release from IL-3-primed peripheral blood basophils. IFN-γ induces CCL13 in bronchial epithelial cell lines, endothelial cells, and chondrocytes, and a synergistic effect is obtained with INF-γ and TNF-α or IL-1 in chondrocytes. CCL13 is processed and inactivated by MMP-12.
Interaction
Monocytes, dendritic cells, basophils, eosinophils, T cells
Ligand/Receptor
CCR2, CCR3, and CCR5
Cell Type
Endothelial cells, Epithelial cells, Fibroblasts, Macrophages
Biology Area
Cell Biology, Signal Transduction
Molecular Family
Cytokines/Chemokines
Antigen References
  1. Uguccioni M, et al. 1996. J. Exp. Med. 183:2379.
  2. Godiska R, et al. 1997. J. Leuko. Biol. 61:353.
  3. Kalayci O, et al. 2004. J. Asthma 41:27.
  4. Iwamoto T, et al. 2007. FEBS J. 274:4904.
  5. Mendez-Enriquez E, et al. 2008. Clin. Exp. Immunol. 152:354.
  6. Hintzen C, et al. 2009. Arthritis Rheum. 60:1932.
  7. Dean RA, et al. 2008. Blood 112:3455.
  8. Breland UM, et al. 2010. Cardiovasc. Res. 86:265.
Gene ID
6357 View all products for this Gene ID
UniProt
View information about CCL13 on UniProt.org
Go To Top Version: 2    Revision Date: 08/25/2022

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • Purified anti-human CCL13 (MCP-4)

    3G4_Purified_CCL13_Antibody_122818.PNG
ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account